Patents by Inventor Wade S. Blair

Wade S. Blair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE
    Publication number: 20250059261
    Abstract: Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.
    Type: Application
    Filed: July 12, 2024
    Publication date: February 20, 2025
    Inventors: Manuel Baca, Wade S. Blair, Brian A. Carr, Sheila B. Clancy, Joshua Goldsmith, Magdeleine S. Hung, Manu Kanwar, Brian Moldt, Mark Nagel, Craig S. Pace, YenRu Pan, Heather T. Stephenson, Nathan D. Thomsen
  • CAPSID INHIBITORS FOR THE PREVENTION OF HIV
    Publication number: 20240051941
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Application
    Filed: May 10, 2023
    Publication date: February 15, 2024
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Capsid inhibitors for the prevention of HIV
    Patent number: 11807625
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: November 7, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Capsid inhibitors for the prevention of HIV
    Patent number: 11685728
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 27, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE
    Publication number: 20230056252
    Abstract: Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 23, 2023
    Inventors: Manuel Baca, Wade S. Blair, Brian A. Carr, Sheila B. Clancy, Joshua Goldsmith, Magdeleine S. Hung, Manu Kanwar, Brian Moldt, Mark Nagel, Craig S. Pace, YenRu Pan, Heather T. Stephenson, Nathan D. Thomsen
  • CAPSID INHIBITORS FOR THE PREVENTION OF HIV
    Publication number: 20210188815
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Application
    Filed: November 25, 2020
    Publication date: June 24, 2021
    Applicant: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Antiviral indoleoxoacetyl piperazine derivatives
    Patent number: 6469006
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: October 22, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wade S. Blair, Milind Deshpande, Haiquan Fang, Pin-Fang Lin, Timothy P. Spicer, Owen B. Wallace, Hui Wang, Tao Wang, Zhongxing Zhang, Kap-Sun Yeung
  • Method of assaying for RNA: protein interactions
    Patent number: 6261772
    Abstract: The present invention relates, in general to an assay method, and, in particular, to an in vivo method of assaying the interaction of RNA with proteins. The invention relates to a kit suitable for use in connection with such method.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: July 17, 2001
    Assignee: Duke University
    Inventors: Bryan R. Cullen, Wade S. Blair